Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AXSM NYSE:BHC NASDAQ:JAZZ On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAXSMAxsome Therapeutics$235.32+5.0%$178.40$96.09▼$235.92$11.53B0.59912,690 shs815,286 shsBHCBausch Health Cos$5.27-2.7%$5.43$4.41▼$8.69$2.02B0.421.80 million shs2.10 million shsJAZZJazz Pharmaceuticals$232.33+2.0%$195.49$103.60▼$235.00$14.30B0.27991,426 shs918,035 shsReduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Click the link to learn more about using beta to protect your portfolio.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAXSMAxsome Therapeutics+5.04%+5.70%+31.96%+28.63%+122.69%BHCBausch Health Cos-2.59%-6.90%-8.03%-9.85%+12.74%JAZZJazz Pharmaceuticals+1.97%+1.65%+18.95%+39.71%+125.76%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAXSMAxsome Therapeutics$235.32+5.0%$178.40$96.09▼$235.92$11.53B0.59912,690 shs815,286 shsBHCBausch Health Cos$5.27-2.7%$5.43$4.41▼$8.69$2.02B0.421.80 million shs2.10 million shsJAZZJazz Pharmaceuticals$232.33+2.0%$195.49$103.60▼$235.00$14.30B0.27991,426 shs918,035 shsReduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Click the link to learn more about using beta to protect your portfolio.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAXSMAxsome Therapeutics+5.04%+5.70%+31.96%+28.63%+122.69%BHCBausch Health Cos-2.59%-6.90%-8.03%-9.85%+12.74%JAZZJazz Pharmaceuticals+1.97%+1.65%+18.95%+39.71%+125.76%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAXSMAxsome Therapeutics 2.90Moderate Buy$251.266.78% UpsideBHCBausch Health Cos 1.80Reduce$8.0051.95% UpsideJAZZJazz Pharmaceuticals 2.83Moderate Buy$230.56-0.76% DownsideCurrent Analyst Ratings BreakdownLatest AXSM, JAZZ, and BHC Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/7/2026JAZZJazz Pharmaceuticals Morgan StanleySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOverweight$245.005/6/2026JAZZJazz Pharmaceuticals Raymond James FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform$239.005/6/2026JAZZJazz Pharmaceuticals TD CowenSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$220.00 ➝ $275.005/6/2026JAZZJazz Pharmaceuticals Robert W. BairdSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$252.005/6/2026JAZZJazz Pharmaceuticals BarclaysSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$225.00 ➝ $234.005/6/2026JAZZJazz Pharmaceuticals Royal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$195.00 ➝ $258.005/6/2026JAZZJazz Pharmaceuticals Wells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$250.00 ➝ $265.005/5/2026AXSMAxsome Therapeutics Deutsche Bank AktiengesellschaftSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$280.005/5/2026AXSMAxsome Therapeutics Needham & Company LLCSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$225.00 ➝ $255.005/5/2026AXSMAxsome Therapeutics Royal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$242.00 ➝ $302.005/5/2026AXSMAxsome Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$270.00 ➝ $290.00(Data available from 5/14/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAXSMAxsome Therapeutics$638.50M18.97N/AN/A$1.06 per share222.00BHCBausch Health Cos$10.27B0.19$7.11 per share0.74($2.89) per share-1.82JAZZJazz Pharmaceuticals$4.27B3.42$16.58 per share14.01$72.24 per share3.22Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAXSMAxsome Therapeutics-$183.17M-$3.73N/A58.39N/A-26.59%-267.16%-28.53%N/ABHCBausch Health Cos$157M-$3.24N/A1.38N/A-11.47%-2,922.77%5.63%7/29/2026 (Estimated)JAZZJazz Pharmaceuticals-$356.15M-$0.02N/A10.470.410.66%14.56%5.25%N/ALatest AXSM, JAZZ, and BHC EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/5/2026Q1 2026JAZZJazz Pharmaceuticals$4.67$6.34+$1.67$4.43$978.66 million$974.98 million5/4/2026Q1 2026AXSMAxsome Therapeutics-$0.85-$1.26-$0.41-$1.26$191.10 million$191.20 million4/29/2026Q1 2026BHCBausch Health Cos$0.81$0.78-$0.03-$3.76$2.37 billion$2.46 billion3/31/2026Q1 2026JAZZJazz PharmaceuticalsN/A$6.34N/A$4.43N/A$1.07 billion2/25/2026Q4 2025JAZZJazz Pharmaceuticals$6.49$6.64+$0.15$3.21$1.17 billion$1.20 billion2/23/2026Q4 2025AXSMAxsome Therapeutics-$0.70-$0.56+$0.14-$0.56$191.33 million$196.00 million2/18/2026Q4 2025BHCBausch Health Cos$1.21$1.08-$0.13-$0.30$2.71 billion$2.78 billionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthAXSMAxsome TherapeuticsN/AN/AN/AN/AN/ABHCBausch Health CosN/AN/AN/AN/AN/AJAZZJazz PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAXSMAxsome Therapeutics2.271.391.32BHCBausch Health Cos54.681.320.97JAZZJazz Pharmaceuticals0.952.041.85Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAXSMAxsome Therapeutics81.49%BHCBausch Health Cos78.65%JAZZJazz Pharmaceuticals89.14%Insider OwnershipCompanyInsider OwnershipAXSMAxsome Therapeutics20.60%BHCBausch Health Cos20.67%JAZZJazz Pharmaceuticals4.30%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAXSMAxsome Therapeutics38051.46 million40.86 millionOptionableBHCBausch Health Cos20,300373.81 million296.55 millionOptionableJAZZJazz Pharmaceuticals2,89062.74 million60.05 millionOptionableAXSM, JAZZ, and BHC HeadlinesRecent News About These CompaniesDoes Epidiolex Make Jazz Pharmaceuticals a Unique Cannabis Stock?May 13 at 9:00 AM | zacks.comJazz Pharmaceuticals to Participate in Upcoming Investor ConferencesMay 12 at 4:15 PM | prnewswire.comHere's Why Jazz Pharmaceuticals (JAZZ) is a Strong Momentum StockMay 12 at 10:51 AM | zacks.comInternational Markets and Jazz (JAZZ): A Deep Dive for InvestorsMay 11 at 10:16 AM | zacks.comUBS Remains a Hold on Jazz Pharmaceuticals (JAZZ)May 10, 2026 | theglobeandmail.comJazz Pharmaceuticals Signals Confidence After Record QuarterMay 9, 2026 | theglobeandmail.comRaymond James Reaffirms Their Buy Rating on Jazz Pharmaceuticals (JAZZ)May 9, 2026 | theglobeandmail.comAnalysts Offer Insights on Healthcare Companies: Jazz Pharmaceuticals (JAZZ) and SOPHiA GENETICS (SOPH)May 8, 2026 | theglobeandmail.comHere's Why Jazz Pharmaceuticals (JAZZ) is a Strong Value StockMay 8, 2026 | zacks.comIs It Time To Reevaluate Jazz Pharmaceuticals (JAZZ) After A 125% One Year Rally?May 7, 2026 | finance.yahoo.comAnalysts Have Conflicting Sentiments on These Healthcare Companies: DENTSPLY SIRONA (XRAY) and Jazz Pharmaceuticals (JAZZ)May 7, 2026 | theglobeandmail.comRoyal Bank Of Canada Issues Positive Forecast for Jazz Pharmaceuticals (NASDAQ:JAZZ) Stock PriceMay 7, 2026 | americanbankingnews.comJazz Pharmaceuticals (NASDAQ:JAZZ) Price Target Raised to $265.00 at Wells Fargo & CompanyMay 7, 2026 | americanbankingnews.comJazz reaffirms $4.25B-$4.5B 2026 revenue guidance while targeting an Aug. 25, 2026 PDUFA for Ziihera in GEAMay 6, 2026 | seekingalpha.comJazz: Q1 Earnings SnapshotMay 6, 2026 | chron.comJAZZ Q1 deep dive: Oncology and neuroscience drive double-digit revenue growth, eyes on upcoming approvalsMay 6, 2026 | msn.comJazz Pharmaceuticals (NASDAQ:JAZZ) Surprises With Q1 CY2026 SalesMay 6, 2026 | finance.yahoo.comJazz Pharmaceuticals Q1 Review: The Oncology Pivot Is Real, And The Market Is Still Mispricing ItMay 6, 2026 | seekingalpha.comJazz Pharmaceuticals (NASDAQ:JAZZ) Given New $258.00 Price Target at Royal Bank Of CanadaMay 6, 2026 | marketbeat.comJAZZ Stock Jumps as Q1 Earnings & Sales Surpass ExpectationsMay 6, 2026 | zacks.comJazz Pharmaceuticals (NASDAQ:JAZZ) Given New $265.00 Price Target at Wells Fargo & CompanyMay 6, 2026 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeAXSM, JAZZ, and BHC Company DescriptionsAxsome Therapeutics NASDAQ:AXSM$235.32 +11.29 (+5.04%) Closing price 05/13/2026 04:00 PM EasternExtended Trading$235.82 +0.50 (+0.21%) As of 05/13/2026 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea. It is also developing AXS-05, which is in Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation; AXS-07, an investigational medicine that has completed Phase III trials for the acute treatment of migraine; AXS-12, an investigational medicine, which is in Phase III trial to treat narcolepsy; AXS-14, a selective and potent norepinephrine reuptake inhibitor that has completed Phase III trial for the treatment of fibromyalgia and other conditions; and solriamfetol, a dual-acting dopamine and norepinephrine reuptake inhibitor, which has completed a Phase 2 trial for treating attention-deficit/hyperactivity disorder, and is in phase 2 major depressive, binge eating, and shift work disorder. Axsome Therapeutics, Inc. has a research collaboration agreement with Duke University for evaluating AXS-05 in smoking cessation. The company was incorporated in 2012 and is based in New York, New York.Bausch Health Cos NYSE:BHC$5.26 -0.15 (-2.68%) Closing price 05/13/2026 03:59 PM EasternExtended Trading$5.21 -0.06 (-1.10%) As of 04:47 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Bausch Health Companies Inc. operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health. The company operates through five segments: Salix, International, Solta Medical, Diversified, and Bausch + Lomb. The Salix segment provides gastroenterology products in the United States. The International segment sells aesthetic medical devices, branded pharmaceuticals, generic pharmaceuticals, and OTC products internationally. The Solta Medical segment engages in the sale of aesthetic medical devices. The Diversified segment offers pharmaceutical products in the areas of neurology and certain other therapeutic classes; generic products; ortho dermatologic; and dentistry products in the United States. The Bausch + Lomb segment offers products in the areas of vision care, surgical, and ophthalmic pharmaceuticals products. The company was formerly known as Valeant Pharmaceuticals International, Inc. and changed its name to Bausch Health Companies Inc. in July 2018. Bausch Health Companies Inc. is headquartered in Laval, Canada.Jazz Pharmaceuticals NASDAQ:JAZZ$232.33 +4.49 (+1.97%) Closing price 05/13/2026 04:00 PM EasternExtended Trading$228.75 -3.58 (-1.54%) As of 04:26 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia. It also develops Zanidatamab to treat HER2-expressing gastroesophageal adenocarcinoma (GEA), and patients with HER2-expressing metastatic GEA; Zepzelca for the treatment of patients with select relapsed/refractory solid tumors based on limited response in three solid tumor cohorts; JZP815, a pan-RAF kinase inhibitor that targets components of the mitogen-activated protein kinase; JZP898, a conditionally-activated interferon alpha molecule; Epidiolex to treat LGS, DS, and TSC; Suvecaltamide to treat parkinson's disease tremor; JZP150, a fatty acid amide hydrolase inhibitor program to treat post-traumatic stress disorder; and JZP441 to treat narcolepsy, IH, and other sleep disorders. The company has licensing and collaboration agreements with XL-protein GmbH to extend the plasma half-life of selected asparaginase product candidates; Redx Pharma plc for preclinical activities Ras/Raf/MAP kinase pathway program; and Autifony Therapeutics Limited on discovering and developing drug candidates targeting two different ion channel targets associated with neurological disorders. The company was incorporated in 2003 and is headquartered in Dublin, Ireland. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Nebius Upside Expands as AI Feedback Loop Intensifies Insider Trades: Okta and Abbott See Buys, Micron Insiders Sell Qualcomm Stock Doubles: New Era? Or Another False Start? D-Wave Earnings Looked Weak, But Investors May Be Missing This A Quantum Shift: Why Speculative Money Is Ditching AI Plug Power Flips The Switch On Profitability Reading the Stripes: Is The Industrial Recession Over? How Bad Could Tesla’s Cybertruck Recall Be for Shares? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
